転移性がん治療薬市場 - 2031年の成長予測、統計および事実

  • Report Code : TIPRE00028616
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 233
Buy Now

[調査レポート]転移性がん治療薬の市場規模は、2021 年の 511 億 5,797 万米ドルから 2028 年までに 683 億 4,954 万米ドルに達すると予測されています。2021 年から 2028 年にかけて CAGR 4.2% で成長すると予想されています。



転移性がんは、他の身体部位に転移する進行期のがんと定義されており、進行期のがんの治療に使用される薬剤は転移性がん治療薬として知られています。これらの薬は、化学療法、免疫療法、標的療法などのさまざまな治療法で使用されます。



転移性がん治療薬市場は、がんの種類、投与経路、薬剤に基づいて分析されています。クラス、製品、エンド ユーザー、および地理。市場は、地理的に、北米、ヨーロッパ、アジア太平洋、中東およびアフリカ、南および中央アメリカに広く分割されています。このレポートは、市場の洞察と詳細な分析を提供し、転移性がん治療薬の市場規模、トレンド、技術の進歩、市場のダイナミクスなどのパラメーターを強調し、世界をリードする市場プレーヤーの競争状況の分析も行います。< /p>

戦略的洞察



転移性がん治療薬市場は、転移性がんの有病率が高いことと、がん治療の開発を支援する政府の取り組みに起因しています.ただし、腫瘍治療薬の高コストにより、転移性がん治療薬市場の成長が制限されています。



転移性がん治療薬市場における有利な地域



市場Insights 転移性がんの高い有病率



がんは、世界中の社会に大きな影響を与える健康状態の 1 つです。国立がん研究所が提供したデータによると、2020 年に米国では 1,806,590 人ががんで苦しんでおり、606,520 人ががんで死亡しています。米国がん研究所によると、2020 年には世界中で 18,100 例が活動していました。さらに、世界保健機関 (WHO) は、10,000 人の死亡、つまり世界の死亡者の 6 人に 1 人が癌によるものであると述べています。最も一般的ながんの種類は、肺がん、乳がん、結腸がん、直腸がん、および前立腺がんです。この状態は、毎年 400,000 人の子供に発症します。ヘリコバクター ピロリ、B 型肝炎ウイルス、ヒトパピローマ ウイルス (HPV)、C 型肝炎ウイルス、エプスタイン-バーウイルスなどの発がん性感染症は、2018 年に世界のがん症例の 13% を引き起こしました。国際がん研究機関 (IARC) は、世界中のがんの新規症例数とがん関連の死亡者数が、2018 年の 1,640 万人から 2040 年までに 1.6 ~ 1.7 倍に増加し、2,950 万人に達すると予測しています。さらに、American Society によると、臨床腫瘍学の報告によると、2021 年に米国で 290,560 人 (女性 287,850 人、男性 2,710 人) が浸潤性乳がんと診断されました。女性の乳がんは現在、肺がんを上回り、世界で最も一般的ながんの種類として認識されています。 2020 年には、約 2,261,419 人の女性が乳がんと診断されました。



過去数十年にわたって米国でがんについて記録されたすべての観察結果の中で、変化していない統計が 1 つあります。それは転移性がんの説明です。毎年、すべてのがんによる死亡の最大 90% を占めています。これらの数字は、がんがその発生点を超えて広がるときに発生する転移を治療するための新しい方法を見つけるための医師や研究者の動機となっています.米国では、女性の 6% が最初の診断で転移性乳がんと診断されました。このような転移性がんの有病率の上昇は、転移性がん治療薬市場の成長を後押ししています。



北米では、カナダは予測期間中にかなりの成長を遂げると予想されています。カナダで使用されている主な免疫療法薬は、イピリムマブ(ヤーボイ)、ペムブロリズマブ(キイトルーダ)、ニボルマブ(オプジーボ)、デュルバルマブ(イミフィンジ)、アテゾリズマブ(テセントリク)です。ただし、市場全体の成長をもたらす準備ができている他のチェックポイント阻害剤があります.



がんの種類に基づく洞察



がんの種類に基づく、転移性がん治療薬市場は、乳がん、肺がん、肝臓がん、血液がん、脳がん、前立腺がん、膵臓がんなどに分割されています。乳がんセグメントは 2021 年に最大の市場シェアを占め、予測期間中に最高の CAGR を登録すると予想されます。



がんの種類別の転移性がん治療薬市場 - 2021 年および 2028 年



投与経路に基づく洞察



投与経路に基づいて、転移性がん治療薬市場は静脈内、筋肉内、口頭、その他。静脈内セグメントは 2021 年に最大の市場シェアを占め、予測期間中に最高の CAGR を登録すると予想されます。



薬物クラスベースの洞察



薬物クラスに基づいて、転移性がん治療薬市場は、HER2 阻害剤、免疫チェックポイント阻害剤、PARP 阻害剤、キナーゼ阻害剤などに分類されます。 PARP 阻害剤セグメントは、2021 年に最大の市場シェアを占めました。ただし、HER2 阻害剤セグメントは、予測期間中に最高の CAGR を記録すると予想されます。



製品ベースの洞察

製品に基づいて、転移性がん治療薬市場は、ブランドとジェネリックおよびバイオシミラーに分かれています。ブランドセグメントは、2021 年に大きな市場シェアを占めました。ただし、ジェネリックおよびバイオシミラーセグメントは、予測期間中により高い CAGR を記録すると推定されています。



エンドユーザーベースの洞察< /h3>

エンドユーザーに基づいて、転移性がん治療薬市場は病院、専門クリニックなどに分割されます。病院セグメントは 2021 年に最大のシェアを占めましたが、専門クリニック セグメントは予測期間中に最高の CAGR を記録すると推定されています。



製品の発売と承認は、一般的に採用されているものの 1 つです。グローバルなフットプリントと製品ポートフォリオを拡大するための企業による戦略。転移性がん治療薬市場のプレーヤーは、顧客層を拡大するためのパートナーシップ戦略にも焦点を当てています。これにより、世界中でブランド名を維持することができます。



AbbVie Inc.;アムジェン社;ブリストル・マイヤーズ スクイブ社。 F. HOFFMANN-LA ROCHE LTD.;ノバルティス AG; ASTRAZENECA PLC.; Eli Lilly and Company;メルクKGaA; Pfizer Inc. (Arena Pharmaceutical GmbH);および Johnson and Johnson Services, Inc. は、転移性がん治療薬市場で事業を展開している大手企業です。



Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which segment is dominating the metastatic cancer drug market?

The metastatic cancer drug market, by cancer type, is bifurcated into breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. The breast cancer segment held the largest share in 2021 and is anticipated to register the highest CAGR during the forecast period.

Who are the major players in market the metastatic cancer drug market?

The metastatic cancer drug market majorly consists of the players such as AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., Novartis AG, ASTRAZENECA PLC., Eli Lilly and Company, MERCK KGaA, and Pfizer Inc. (Arena Pharmaceutical GmbH) amongst others.

What are the driving factors for the metastatic cancer drug market across the country?

The factors that are driving and restraining factors that will affect the metastatic cancer drugs market in the coming years. The growth of the market is attributed to some key driving factors such as increasing prevalence of cancer and government initiatives to support drug developments for cancer treatment. However, high cost of oncology drugs is likely to hinder the market growth.

What is the metastatic cancer drug market?

Cancer that spreads from where it started to a distant part of the body is called metastatic cancer. The process by which cancer cells spread to other parts of the body is called metastasis. Metastatic cancer is an advanced cancer stage that spread to the other body parts and the drugs used for the treatment of advanced stage cancer are known as metastatic cancer drugs. These drugs are used through various therapies such as chemotherapy, immunotherapy, and targeted therapy.

The List of Companies - Metastatic Cancer Drug Market

  1. AbbVie Inc.
  2. Amgen Inc.
  3. Bristol-Myers Squibb Company
  4. F. HOFFMANN-LA ROCHE LTD.
  5. Novartis AG
  6. ASTRAZENECA PLC.
  7. Eli Lilly and Company
  8. MERCK KGaA
  9. Pfizer Inc. (Arena Pharmaceutical GmbH)

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports